CN104902921A - 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物 - Google Patents

用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物 Download PDF

Info

Publication number
CN104902921A
CN104902921A CN201480003919.4A CN201480003919A CN104902921A CN 104902921 A CN104902921 A CN 104902921A CN 201480003919 A CN201480003919 A CN 201480003919A CN 104902921 A CN104902921 A CN 104902921A
Authority
CN
China
Prior art keywords
months
amount
pharmaceutical composition
combination
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480003919.4A
Other languages
English (en)
Chinese (zh)
Inventor
米丽娅姆·基德隆
埃胡德·阿比特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oramed Ltd
Original Assignee
Oramed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2013/050007 external-priority patent/WO2013102899A1/en
Application filed by Oramed Ltd filed Critical Oramed Ltd
Priority to CN201910287860.0A priority Critical patent/CN110151979A/zh
Publication of CN104902921A publication Critical patent/CN104902921A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201480003919.4A 2013-01-03 2014-01-02 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物 Pending CN104902921A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910287860.0A CN110151979A (zh) 2013-01-03 2014-01-02 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ILPCT/IL2013/050007 2013-01-03
PCT/IL2013/050007 WO2013102899A1 (en) 2012-01-03 2013-01-03 Methods and compositions for treating diabetes
US201361763996P 2013-02-13 2013-02-13
US61/763,996 2013-02-13
PCT/IL2014/050007 WO2014106846A2 (en) 2013-01-03 2014-01-02 Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910287860.0A Division CN110151979A (zh) 2013-01-03 2014-01-02 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物

Publications (1)

Publication Number Publication Date
CN104902921A true CN104902921A (zh) 2015-09-09

Family

ID=51062529

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910287860.0A Pending CN110151979A (zh) 2013-01-03 2014-01-02 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物
CN201480003919.4A Pending CN104902921A (zh) 2013-01-03 2014-01-02 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910287860.0A Pending CN110151979A (zh) 2013-01-03 2014-01-02 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物

Country Status (5)

Country Link
US (4) US20150335715A1 (enExample)
EP (2) EP2941267B1 (enExample)
JP (5) JP2016505613A (enExample)
CN (2) CN110151979A (enExample)
WO (1) WO2014106846A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109806386A (zh) * 2017-11-20 2019-05-28 江苏恒瑞医药股份有限公司 Fxr激动剂与glp-1类似物的药物组合物和用途
WO2021142736A1 (en) * 2020-01-16 2021-07-22 Shanghai Benemae Pharmaceutical Corporation Dosing regimen of glp-1
WO2021142733A1 (en) * 2020-01-16 2021-07-22 Shanghai Benemae Pharmaceutical Corporation Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2670856T3 (es) * 2005-09-06 2018-06-01 Oramed Pharmaceuticals Inc. Métodos y composiciones para la administración oral de proteínas
RU2504373C2 (ru) 2008-03-26 2014-01-20 ОРАМЕД Лтд. Способы и композиции для перорального введения протеинов
BRPI0908292B1 (pt) 2008-05-05 2022-09-20 Oramed Ltd Métodos e composições para administração oral de exenatida
JP6174601B2 (ja) 2012-01-03 2017-08-02 オラムド エルティーディー． 糖尿病を処置するための方法及び組成物
WO2013114369A1 (en) 2012-02-01 2013-08-08 Oramed Ltd Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same
US20150335715A1 (en) 2013-01-03 2015-11-26 Oramed Ltd. Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof
SG11201507411TA (en) 2013-03-13 2015-10-29 Astellas Pharma Inc Guanidinobenzoic acid ester compound
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3197913B1 (en) * 2014-09-22 2019-08-28 Hadasit Medical Research Services And Development Alpha-1 anti-trypsin for treating liver diseases
KR102399254B1 (ko) 2016-09-28 2022-05-17 아이거 바이오파마슈티컬스 인코포레이티드 비-알코올성 지방간염의 치료를 위한 방법 및 약제학적 조성물
CA3096004A1 (en) * 2018-06-11 2019-12-19 Oramed Ltd. Recombinant protease inhibitor-containing compositions, methods for producing same and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101094689A (zh) * 2004-11-01 2007-12-26 安米林药品公司 治疗肥胖以及肥胖相关疾病和病症的方法
CN101547702A (zh) * 2005-09-06 2009-09-30 奥拉姆德医药公司 用于口服给药蛋白质的方法和组合物
CN102026646A (zh) * 2008-05-05 2011-04-20 奥拉姆德有限公司 用于口服给予艾塞那肽的方法和组合物
CN102105159A (zh) * 2008-06-17 2011-06-22 印第安纳大学研究及科技有限公司 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
CN102123697A (zh) * 2008-08-18 2011-07-13 奥拉姆德有限公司 用于口服给予蛋白质的方法和组合物
CN102219850A (zh) * 2011-05-03 2011-10-19 上海格尼生物技术有限公司 新的长效glp-1化合物

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
JPS6350793A (ja) 1986-08-20 1988-03-03 株式会社東芝 高速増殖炉の崩壊熱除去システム
US5034415A (en) 1987-08-07 1991-07-23 Century Laboratories, Inc. Treatment of diabetes mellitus
ES2045276T3 (es) 1988-07-21 1994-01-16 Hoffmann La Roche Preparacion de insulina
JPH02250823A (ja) 1989-03-24 1990-10-08 Tsumura & Co マイクロカプセル剤およびその製造方法
GB9007052D0 (en) 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
CA2149223C (en) * 1992-11-17 2007-04-24 Jonathan Edward Lightner Genes for microsomal delta-12 fatty acid desaturases and related enzymes from plants
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
IL114673A (en) 1995-07-19 2000-12-06 Hadasit Med Res Service Pharmaceutical compositions containing protein for oral administration
JPH09208485A (ja) 1996-01-31 1997-08-12 Teijin Ltd ペプチド・蛋白質性薬物の水難溶性組成物
ES2319936T5 (es) 1996-08-08 2013-06-24 Amylin Pharmaceuticals, Inc. Regulación de la motilidad gastrointestinal
JPH10330287A (ja) 1997-03-31 1998-12-15 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸からなる消化管吸収促進剤およびそれを含有する薬剤
JP2000128805A (ja) 1998-10-27 2000-05-09 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸および高分子ゲルからなる経粘膜吸収促進剤及びそれを含有する薬剤
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
ATE464062T1 (de) * 1999-10-04 2010-04-15 Novartis Vaccines & Diagnostic Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi
JP2001240558A (ja) 2000-02-29 2001-09-04 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸を経粘膜吸収促進剤として含有する固形製剤。
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
KR20010069322A (ko) 2001-03-08 2001-07-25 서종수 휴대형정보단말기 또는 화상이동통신장치를 이용한전자경매방법
KR20010069433A (ko) 2001-03-22 2001-07-25 김윤완 노루궁뎅이버섯을 이용한 건강 보조 식품
CN1160122C (zh) 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
EP1414474A4 (en) 2001-07-18 2005-06-29 Solae Llc PROTEIN BOWMAN BIRK HEMMER CONCENTRATE AND MANUFACTURING METHOD THEREFOR
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20050143303A1 (en) 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
CA2563533C (en) 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capable of facilitating penetration across a biological barrier
CN103223160B (zh) 2004-07-19 2015-02-18 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
WO2006025882A2 (en) 2004-08-25 2006-03-09 The Uab Research Foundation Absorption enhancers for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
WO2007022518A2 (en) * 2005-08-19 2007-02-22 Amylin Pharmaceuticals, Inc. New uses of glucoregulatory proteins
US20070086972A1 (en) 2005-09-12 2007-04-19 Jacob Birnbaum Hair growth compositions and methods for treating hair loss or related conditions
US20070077283A1 (en) 2005-09-30 2007-04-05 Nastech Pharmaceutical Company Inc. Method of enhancing transmucosal delivery of therapeutic compounds
CN101095942B (zh) 2006-06-30 2011-11-16 北京民海生物科技有限公司 一种包含稳定剂的Exendin-4注射剂药物配方
RU2009120568A (ru) 2006-11-01 2010-12-10 Пронова Биофарма Норге Ас (No) Композиция
WO2008117062A1 (en) 2007-03-28 2008-10-02 Aker Biomarine Asa Bioeffective krill oil compositions
RU2504373C2 (ru) 2008-03-26 2014-01-20 ОРАМЕД Лтд. Способы и композиции для перорального введения протеинов
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
US20110092592A1 (en) * 2008-06-13 2011-04-21 Takashi Yano Diagnosis and treatment of hepatic disorder
WO2009154230A1 (ja) 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
JP2011526888A (ja) 2008-07-01 2011-10-20 ザ・ジョンズ・ホプキンス・ユニバーシティ 治療薬を標的送達するための経口速溶性薄膜
UY32177A (es) 2008-10-16 2010-05-31 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
HRP20190732T1 (hr) 2009-05-08 2019-06-14 Basf As Polinezasićene masne kiseline za liječenje bolesti povezanih s kardiovaskularnim, metaboličkim i upalnim područjima bolesti
EP2488180A4 (en) 2009-10-12 2013-03-27 Ipca Lab Ltd PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT / PROPHYLAXIS OF NON ALCOHOLIC HEPATIC STEATOSIS
US20120329993A1 (en) 2009-12-30 2012-12-27 Legal Department Soy whey protein compositions and methods for recovering same
US20130273154A1 (en) 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
KR20230051307A (ko) * 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
JP6093699B2 (ja) * 2010-07-06 2017-03-08 ヤンセン ファーマシューティカ エヌ．ベー． 糖尿病のコ−セラピー治療のための製剤
ES2659763T3 (es) * 2011-02-14 2018-03-19 The Regents Of The University Of Michigan Composiciones y procedimientos para el tratamiento de obesidad y trastornos relacionados
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
CN103906528A (zh) * 2011-06-24 2014-07-02 安米林药品有限责任公司 用glp-1受体激动剂的缓释制剂治疗糖尿病的方法
CN103717789A (zh) 2011-07-15 2014-04-09 明通企业股份有限公司 填充式工件表面饰化方法
US9458214B2 (en) * 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
JP6174601B2 (ja) 2012-01-03 2017-08-02 オラムド エルティーディー． 糖尿病を処置するための方法及び組成物
WO2013114369A1 (en) * 2012-02-01 2013-08-08 Oramed Ltd Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same
EP2844269A4 (en) * 2012-03-28 2016-01-06 Amylin Pharmaceuticals Llc TRANSMUCOSAL ADMINISTRATION OF MANIPULATED POLYPEPTIDES
US20150335715A1 (en) 2013-01-03 2015-11-26 Oramed Ltd. Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101094689A (zh) * 2004-11-01 2007-12-26 安米林药品公司 治疗肥胖以及肥胖相关疾病和病症的方法
CN101547702A (zh) * 2005-09-06 2009-09-30 奥拉姆德医药公司 用于口服给药蛋白质的方法和组合物
CN102026646A (zh) * 2008-05-05 2011-04-20 奥拉姆德有限公司 用于口服给予艾塞那肽的方法和组合物
CN102105159A (zh) * 2008-06-17 2011-06-22 印第安纳大学研究及科技有限公司 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
CN102123697A (zh) * 2008-08-18 2011-07-13 奥拉姆德有限公司 用于口服给予蛋白质的方法和组合物
CN102219850A (zh) * 2011-05-03 2011-10-19 上海格尼生物技术有限公司 新的长效glp-1化合物

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
D SHYANGDAN ET AL: "Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review", 《HEALTH TECHNOLOGY ASSESSMENT》 *
K GOWTHAMARAJAN ET AL: "Oral Insulin – Fact or Fiction?", 《RESONANCE》 *
KYEONGSOON PARK ET AL: "Oral protein delivery: Current status and future prospect", 《REACTIVE & FUNCTIONAL POLYMERS》 *
MARIKO MORISHITA ET AL: "Novel oral microspheres of insulin with protease inhibitor protecting from enzymatic degradation", 《INTERNATIONAL JOURNAL OF PHARMACEUTICS》 *
NADEAU KJ ET AL: "Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents", 《PEDIATRIC DIABETES》 *
R.L.DRAKE: "不同胰岛素剂量对肝脂肪生成的效应", 《解剖学研究》 *
南瑛等: "胰岛素对大鼠肝细胞损伤的保护作用", 《现代医药卫生》 *
南瑛等: "胰岛素对大鼠肝细胞损伤的保护及其抗炎机制", 《细胞与分子免疫学杂志》 *
方文莉等: "NALP3炎性体在小鼠非酒精性脂肪性肝炎发病中的作用", 《肝脏》 *
焦雪琴等: "糖尿病与肝脏病的关系", 《职业与健康》 *
王咏波等: "胰岛素治疗对2型糖尿病大鼠肝脂质含量及胰岛素抵抗的影响", 《中华肝脏病杂志》 *
范建高等: "《脂肪肝》", 30 June 2000 *
许曼音: "《糖尿病学》", 31 May 2010, 上海：上海科学技术出版社 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109806386A (zh) * 2017-11-20 2019-05-28 江苏恒瑞医药股份有限公司 Fxr激动剂与glp-1类似物的药物组合物和用途
WO2021142736A1 (en) * 2020-01-16 2021-07-22 Shanghai Benemae Pharmaceutical Corporation Dosing regimen of glp-1
WO2021142733A1 (en) * 2020-01-16 2021-07-22 Shanghai Benemae Pharmaceutical Corporation Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs
EP4090355A4 (en) * 2020-01-16 2023-12-06 Shanghai Benemae Pharmaceutical Corporation COMBINATION THERAPY COMPRISING GLP-1 AND/OR GLP-1 ANALOGUE AND INSULIN AND/OR INSULIN ANALOGUE

Also Published As

Publication number Publication date
JP2020180126A (ja) 2020-11-05
EP2941267A4 (en) 2016-06-22
EP4215205A1 (en) 2023-07-26
HK1217291A1 (en) 2017-01-06
EP2941267B1 (en) 2022-11-16
EP2941267A2 (en) 2015-11-11
WO2014106846A3 (en) 2015-01-29
JP2016505613A (ja) 2016-02-25
CN110151979A (zh) 2019-08-23
WO2014106846A2 (en) 2014-07-10
US10967051B2 (en) 2021-04-06
US20150335715A1 (en) 2015-11-26
US20190209655A1 (en) 2019-07-11
JP2023002570A (ja) 2023-01-10
US20220000986A1 (en) 2022-01-06
JP2025106279A (ja) 2025-07-15
JP2018197240A (ja) 2018-12-13
US20240181018A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
US10967051B2 (en) Methods and compositions for treating NAFLD, hepatic steatosis, and sequelae thereof
US20230210956A1 (en) Methods and compositions for treating diabetes
ES2670856T3 (es) Métodos y composiciones para la administración oral de proteínas
RU2494755C2 (ru) Способы и композиции для перорального введения белков
HK1223558A1 (zh) 用於口服给予艾塞那肽的方法和组合物
KR20150127599A (ko) 비알코올성 지방간염을 치료하기 위한 조성물 및 방법
HK1217291B (en) Compositions for use in treating nafld
EP3666262B1 (en) Pharmaceutical oral dosage forms for treatment of metabolic disorders and related diseases through orchestrated release of enterokines
KR20020016944A (ko) 하부 요로증 치료용 의약 조성물
AU2015243030B2 (en) Methods and compositions for oral administration of proteins
HK1203826B (en) Capsules containing oil-based liquid compositions of combined therapeutic agents for treating diabetes
AU2014218446B2 (en) Methods and compositions for oral administration of proteins
MÖSSNER Does Feedback Regulation Exist
HK1155375A (en) Methods and compositions for oral administration of exenatide

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150909